Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Hematology. American Society of Hematology. Education Program|November 21, 2007
Are there circumstances in which phase 2 study results should be practice-changing?Marcie R Tomblyn, J Douglas RizzoSeminars in Oncology|August 27, 2003
New developments in antibody therapy for acute myeloid leukemiaMarcie R Tomblyn, Martin S TallmanBiology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 16, 2010
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial responseMarcie R Tomblyn, Marian Ewell, Christopher Bredeson, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2011
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantationJanelle B Perkins, Jongphil Kim, Claudio Anasetti, et al.Blood|October 2, 2013
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantationChristopher Bredeson, Jennifer LeRademacher, Kazunobu Kato, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2009
Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcomeMichael B Tomblyn, Mukta Arora, K Scott Baker, et al.Pageof 1